Le Lézard
Classified in: Health, Science and technology
Subjects: CALENDAR OF EVENTS, Conference Calls/ Webcasts

Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024


SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 26, 2024, after the close of the market, and provide a corporate update.

Conference Call & Webcast:
  
Date:Tuesday, March 26, 2024
Time:5:00 PM ET
Audio Webcast Only:link
Q&A Participant Registration Link*:link
(https://register.vevent.com/register/BIe69f08fc83634a6aa38bf7081d82c6a2)
  

*Analysts interested in participating in the question-and-answer session will pre-register for the event from the participant registration link above to receive the dial-in numbers and a unique PIN, which are required to access the conference call. They also will have the option to take advantage of a Call Me button and the system will automatically dial out to connect to the Q&A session.

The audio webcast also can be accessed through a link on the Investor Relations section of Aptose's website here. A replay of the webcast will be available on the company's website for 30 days.

The press release, the financial statements and the management's discussion and analysis for the quarter ended September 30, 2023 will be available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml.

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase 1/2 expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in Phase 1 a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies. For more information, please visit www.aptose.com.

For further information, please contact:
  
Aptose Biosciences Inc. LifeSci Advisors, LLC
Susan PietropaoloDan Ferry, Managing Director
Corporate Communications & Investor Relations617-430-7576
201-923-2049[email protected]
[email protected] 



These press releases may also interest you

at 01:39
Hansa Biopharma, "Hansa" , will publish its interim report for January-June 2024 on July 18, 2024. Interested parties may join the Company's quarterly conference call on the same date at 14:00 CEST/8:00 AM EST. The event will be hosted by Søren...

at 01:05
Regulatory News: BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced artificial intelligence (AI) to accelerate biopharma drug discovery, today announces a change to its Executive Leadership Team...

at 00:15
In the news release, AbbVie, Inc.'s Zymaxid tm Implicated in Product Liability Lawsuit Due to Risk of Serious Injury and Death, issued 02-Jul-2024 by Wormington & Bollinger over PRWeb, the source of the release should be "Wormington & Bollinger"...

at 00:00
Author David W. Treaster shares a Christian-based plan that can supplement a cancer patient's medical treatment plan in God Power Cancer Healing Plan: Spiritual Component ($15.99, paperback, 9781662899942; $7.99, e-book, 9781662899959). As long as...

2 jui 2024
In a groundbreaking medical feat, LiverIndia's Dr Karthik Mathivanan, a renowned Liver Transplant surgeon in Chennai with over 15 years of experience in multi-organ transplant surgery, has successfully utilised the emerging field of transplant...

2 jui 2024
Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for 225Ac-FL-020, the company's lead radiopharmaceutical,...



News published on and distributed by: